Nevertheless, the mechanism through which PTEN has been lost and off-target effects remain two important considerations for future clinical trials investigating the targeting of oncomiRs to treat PTEN-deficient prostate cancers [128]. This evidence concerns the gene PTEN and prostate carcinoma.